• Explore /
  • Poster
  • / A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.

A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.

Abstract Poster

Authors

null

Andrew Jared Pellatt

MD Anderson Hematology/Oncology Fellowship, Houston, TX

Andrew Jared Pellatt , Alisha Heather Bent , Christine Megerdichian Parseghian , Benny Johnson , Ryan W Huey , Kanwal Pratap Singh Raghav , Van K. Morris II, Michael J. Overman , Maria Pia Morelli , Jason Willis , Phat Le , John Paul Y.C. Shen , Michael Sangmin Lee , Kristin Alfaro , Kathryn Aziz , Robert J. Kell , Ryan Sun , Scott Kopetz , Arvind Dasari

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05343013

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 136)

DOI

10.1200/JCO.2024.42.3_suppl.136

Abstract #

136

Poster Bd #

J2

Abstract Disclosures

Similar Posters

First Author: Arvind Dasari

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Minimal residual disease assessment in colorectal cancer (MiRDA-C).

Minimal residual disease assessment in colorectal cancer (MiRDA-C).

First Author: Arvind Dasari

First Author: Giulia Maddalena

First Author: Yoshiaki Nakamura